Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sars-CoV2 Clear all
Completed Phase 2 Interventional Results available

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898
View directory record Official record
Conditions
Covid19
Interventions
BGB-DXP593, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

NCT04497987
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
Bamlanivimab, Placebo, Etesevimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 21, 2026, 6:41 PM EDT
Completed No phase listed Observational

Covid Flu A/B and RSV 4 in 1 Diagnostic Test

NCT07308158
View directory record Official record
Conditions
Influenza A, Influenza B, COVID - 19, RSV
Interventions
Investigational Flu A/B Covid-19 and RSV Diagnostic Test
Diagnostic Test
Lead sponsor
iHealth Labs inc
Industry
Eligibility
6 Months and older
Enrollment
1,119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Birmingham, Alabama • Trussville, Alabama • Dublin, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 21, 2026, 6:41 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Flu COVID Vaccine Views

NCT07871448
View directory record Official record
Conditions
Influenza, COVID-19, Vaccination Willingness
Interventions
Survey
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 89 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

NCT05543616
View directory record Official record
Conditions
SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Interventions
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 11 Years
Enrollment
4,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

NCT05567952
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir, placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
67
States / cities
Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 21, 2026, 6:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection

NCT04362865
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

NCT04546581
View directory record Official record
Conditions
COVID, COVID-19, SARS-CoV-2, SARS (Severe Acute Respiratory Syndrome)
Interventions
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo, Remdesivir
Biological · Other · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Colorado Springs, Colorado • Lakewood, Colorado • Westminster, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 21, 2026, 6:41 PM EDT
Recruiting Phase 3 Interventional

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

NCT05261139
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
50
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 21, 2026, 6:41 PM EDT
Completed No phase listed Observational

COVID-19 on Placental Gene Expression and Pathology

NCT04585945
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
Positive for SARS-CoV-2 infection
Diagnostic Test
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

NCT04705831
View directory record Official record
Conditions
Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19
Interventions
Ruconest
Drug
Lead sponsor
IMMUNOe Research Centers
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 21, 2026, 6:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.

NCT05728970
View directory record Official record
Conditions
SARS-CoV-2, Influenza A, Influenza B, COVID-19
Interventions
LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
716 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Garden Grove, California • Lomita, California • DeLand, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions
Hydroxychloroquine Sulfate, Ascorbic Acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 21, 2026, 6:41 PM EDT
Withdrawn Phase 2 Interventional

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

NCT03376854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sars-CoV2
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of Care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Not applicable Interventional

A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests

NCT04568356
View directory record Official record
Conditions
SARS CoV-2
Interventions
Direct Antigen Tests for COVID-19
Diagnostic Test
Lead sponsor
E25Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 21, 2026, 6:41 PM EDT
Withdrawn Phase 2 Interventional

Coronavirus Smell Therapy for Anosmia Recovery

NCT04422275
View directory record Official record
Conditions
Anosmia
Interventions
Budesonide, High-Concentration Essential Oil, Placebo, Low-Concentration Essential Oil
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 21, 2026, 6:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID Card Pilot Study to Detect Antibodies to SARS-CoV-2

NCT05196932
View directory record Official record
Conditions
COVID-19, SARS-CoV2 Infection
Interventions
Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 21, 2026, 6:41 PM EDT
Completed No phase listed Observational

Coagulation Changes Associated With COVID-19 Infection

NCT04460664
View directory record Official record
Conditions
COVID, Disseminated Intravascular Coagulation, Coagulation Disorder
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

NCT05077332
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV-2 Infection, SARS-CoV-2 Acute Respiratory Disease, COVID-19
Interventions
Famotidine, Celecoxib, Placebo
Drug · Other
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

NCT05263895
View directory record Official record
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir, PF-07321332
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation

NCT04342728
View directory record Official record
Conditions
COVID, Corona Virus Infection
Interventions
Ascorbic Acid, Zinc Gluconate, Ascorbic Acid and Zinc Gluconate, Standard of Care
Dietary Supplement · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 21, 2026, 6:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU

NCT04476914
View directory record Official record
Conditions
Respiratory Failure, SARS-CoV 2, Corona Virus Infection, Post Intensive Care Unit Syndrome, Family Members, Post Traumatic Stress Disorder, Anxiety, Depression
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
Aurora, Colorado • New Orleans, Louisiana • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Anosmia Study

NCT04495816
View directory record Official record
Conditions
Anosmia, Covid19
Interventions
Omega-3 Fatty Acid Supplement, Placebo/Control
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 21, 2026, 6:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic

NCT04388605
View directory record Official record
Conditions
Corona Virus Infection, COVID, Pregnancy Related, Early Pregnancy
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
7,965 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 6:41 PM EDT